Entera Bio (ENTX) Stock Price, News & Analysis

Company Overview

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company’s proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio’s pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism. The company’s technology is designed to protect biologic molecules in the gastrointestinal tract and facilitate their absorption.

Founded in 2010 and headquartered in Jerusalem, Israel, Entera Bio conducts its research and development activities through its Israeli operations and collaborates with pharmaceutical and biotechnology partners. The company’s programs are aimed at improving the convenience and potential accessibility of treatments that otherwise require injections.

Key Stats

• Today's Range: $2.45 to $2.52
• 50-Day Range: $2.51 to $3.47
• 52-Week Range: $0.91 to $4.20
• Volume: 420,910 shs
• Average Volume: 1.01 million shs
• Market Capitalization: $434.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.60
• Consensus Rating: Moderate Buy

Entera Bio Stock Analysis - MarketRank™

Entera Bio scored higher than 59% of companies evaluated by MarketBeat, and ranked 230th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Entera Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 4 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Entera Bio has a consensus price target of $9.60, representing about 288.0% upside from its current price of $2.47.

Amount of Analyst Coverage

Entera Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Entera Bio are expected to grow in the coming year, from ($0.40) to ($0.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Entera Bio is -7.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Entera Bio is -7.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Entera Bio has a P/B Ratio of 8.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.82% of the float of Entera Bio has been sold short.

Short Interest Ratio / Days to Cover

Entera Bio has a short interest ratio ("days to cover") of 3.57, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Entera Bio has recently increased by 44.68%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Entera Bio does not currently pay a dividend.

Dividend Growth

Entera Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Entera Bio this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for ENTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

2 people have added Entera Bio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Entera Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.57% of the stock of Entera Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

14.11% of the stock of Entera Bio is held by institutions.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/08/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ENTX
• CIK: 1638097
• Web: www.enterabio.com
• Phone: (722) 532-7151
• Fax: N/A
• Employees: 21
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Entera Bio: $9.60
• High Price Target: $11.00
• Low Price Target: $9.00
• Potential Upside/Downside: +284.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.44 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -147.19%
• Return on Assets: -103.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.98
• Quick Ratio: 8.98

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 10,870.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.29 per share
• Price / Book: 8.62

Miscellaneous

• Outstanding Shares: 173,920,000
• Free Float: 155,538,000
• Market Cap: $434.80 million
• Optionable: Optionable
• Beta: 1.40